Idogen continues its steady path towards clinical trials, and the ongoing pandemic has so far not had any major impact on its operations. During the quarter, the company completed its announced rights issue, which strengthened the balance sheet by SEK 20.6m after costs. EUR 0.55m from Horizon 2020 was recently paid out and an additional EUR 0.73m is expected to be received in H1 2021. Focus remains on the upcoming clinical trials that are set to begin in Q1 2021.

Länk till analysen